Complement activation and bioincompatibility. The terminal complement complex for evaluation and surface modification with heparin for improvement of biomaterials. 1991

T E Mollnes, and V Videm, and J Riesenfeld, and P Garred, and J L Svennevig, and E Fosse, and K Hogasen, and M Harboe
Institute of Immunology and Rheumatology, Rikshospitalet, University of Oslo, Norway.

The degree of biocompatibility of biomaterials can be evaluated using various assay systems detecting activation of the blood cascade systems, leukocytes or platelets. Activation of complement is one mechanism associated with adverse effects observed when bioincompatible materials are used. We present data showing that the terminal complement complex, an indicator of terminal pathway activation, is suitable for evaluation of biocompatibility of biomaterials such as cardiopulmonary bypass devices. Furthermore, our results suggest that bioincompatibility is improved when artificial surfaces are modified with end point attached functionally active heparin.

UI MeSH Term Description Entries
D008422 Materials Testing The testing of materials and devices, especially those used for PROSTHESES AND IMPLANTS; SUTURES; TISSUE ADHESIVES; etc., for hardness, strength, durability, safety, efficacy, and biocompatibility. Biocompatibility Testing,Biocompatible Materials Testing,Hemocompatibility Testing,Testing, Biocompatible Materials,Testing, Hemocompatible Materials,Hemocompatibility Testings,Hemocompatible Materials Testing,Materials Testing, Biocompatible,Materials Testing, Hemocompatible,Testing, Biocompatibility,Testing, Hemocompatibility,Testing, Materials,Testings, Biocompatibility
D010106 Oxygenators Devices which mechanically oxygenate venous blood extracorporeally. They are used in combination with one or more pumps for maintaining circulation during open heart surgery and for assisting the circulation in patients seriously ill with some cardiac and pulmonary disorders. (UMDNS, 1999) Oxygenator
D010107 Oxygenators, Membrane Devices in which blood and oxygen are separated by a semipermeable membrane, generally of Teflon or polypropylene, across which gas exchange occurs. The membrane may be arranged as a series of parallel plates or as a number of hollow fibers; in the latter arrangement, the blood may flow inside the fibers, which are surrounded by gas, or the blood may flow outside the fibers and the gas inside the fibers. (Dorland, 28th ed) Membrane Oxygenator,Membrane Oxygenators,Oxygenator, Membrane
D011095 Polyethylenes Synthetic thermoplastics that are tough, flexible, inert, and resistant to chemicals and electrical current. They are often used as biocompatible materials for prostheses and implants. Ethylene Polymers,Ethene Homopolymers,Homopolymers, Ethene,Polymers, Ethylene
D011134 Polysaccharides Long chain polymeric CARBOHYDRATES composed of MONOSACCHARIDES linked by glycosidic bonds. Glycan,Glycans,Polysaccharide
D011143 Polyvinyl Chloride A polyvinyl resin used extensively in the manufacture of plastics, including medical devices, tubing, and other packaging. It is also used as a rubber substitute. Chloroethylene Polymer,Polychloroethylene,Vinyl Chloride Polymer,Chloroethylene Homopolymer,Geon,PVC,Ultron,Viaflex,Vinylite,Chloride, Polyvinyl,Homopolymer, Chloroethylene,Polymer, Chloroethylene,Polymer, Vinyl Chloride
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D005936 Glucans Polysaccharides composed of repeating glucose units. They can consist of branched or unbranched chains in any linkages. Glucan,Polyglucose,Polyglucoses,Glucan (BO),Glucose Polymer,Polycose,Polymer, Glucose
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin

Related Publications

T E Mollnes, and V Videm, and J Riesenfeld, and P Garred, and J L Svennevig, and E Fosse, and K Hogasen, and M Harboe
January 1996, Nephron,
T E Mollnes, and V Videm, and J Riesenfeld, and P Garred, and J L Svennevig, and E Fosse, and K Hogasen, and M Harboe
February 1990, Kidney international,
T E Mollnes, and V Videm, and J Riesenfeld, and P Garred, and J L Svennevig, and E Fosse, and K Hogasen, and M Harboe
January 1993, Journal of biomaterials science. Polymer edition,
T E Mollnes, and V Videm, and J Riesenfeld, and P Garred, and J L Svennevig, and E Fosse, and K Hogasen, and M Harboe
March 2007, Journal of biomedical materials research. Part A,
T E Mollnes, and V Videm, and J Riesenfeld, and P Garred, and J L Svennevig, and E Fosse, and K Hogasen, and M Harboe
January 2012, Macromolecular bioscience,
T E Mollnes, and V Videm, and J Riesenfeld, and P Garred, and J L Svennevig, and E Fosse, and K Hogasen, and M Harboe
September 2011, Advanced drug delivery reviews,
T E Mollnes, and V Videm, and J Riesenfeld, and P Garred, and J L Svennevig, and E Fosse, and K Hogasen, and M Harboe
July 2005, European journal of anaesthesiology,
T E Mollnes, and V Videm, and J Riesenfeld, and P Garred, and J L Svennevig, and E Fosse, and K Hogasen, and M Harboe
September 2006, The International journal of artificial organs,
T E Mollnes, and V Videm, and J Riesenfeld, and P Garred, and J L Svennevig, and E Fosse, and K Hogasen, and M Harboe
January 1985, Complement (Basel, Switzerland),
T E Mollnes, and V Videm, and J Riesenfeld, and P Garred, and J L Svennevig, and E Fosse, and K Hogasen, and M Harboe
June 1986, Arthritis and rheumatism,
Copied contents to your clipboard!